Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Obsessive-Compulsive Disorder Treatment & Management

  • Author: William M Greenberg, MD; Chief Editor: David Bienenfeld, MD  more...
 
Updated: Apr 19, 2016
 

Approach Considerations

OCD is a chronic illness that usually can be treated in an outpatient setting. The mainstays of treatment of OCD include the use of serotoninergic antidepressant medications, particular forms of behavior therapy (exposure and response prevention and some forms of CBT), education and family interventions, and, in extremely refractory cases, neurosurgery.

Patients who have achieved remission of symptoms with behavior therapy alone may never require medication and may instead need only to return to therapy if they have an exacerbation of their illness. Also, a subset of patients has been treated with a combined approach; these patients can discontinue medication, maintaining a remission with behavioral interventions alone. However, many patients require ongoing medication to prevent relapse.

Consider hospitalization for a patient with OCD if a suicide risk exists or if the individual’s symptoms are sufficiently severe to impair the patient's ability to care for himself/herself safely at home. If inpatient care is necessary, admitting the patient to a psychiatric unit whose staff is familiar with OCD and behavioral therapy is preferable.

Next

Pharmacotherapy

First-line pharmacologic treatments consist of 5-HT reuptake inhibitors, such as the SSRIs (fluoxetine, fluvoxamine, sertraline, paroxetine, citalopram, escitalopram), and clomipramine (Anafranil), a tricyclic antidepressant [TCA] with 5-HT and NE reuptake inhibition. Possible alternatives include venlafaxine, a serotonin norepinephrine reuptake inhibitor (SNRI). All of these are commonly used to treat OCD, although not all have received an indication from the US Food and Drug Administration (FDA) for this disorder.

Unlike in the case of major depression, complete or near-complete remission of OCD symptoms is rare with only serotonergic antidepressant treatment. More typically, perhaps half of patients may experience symptom reductions of 30-50%, as measured by the Y-BOCS, with many other patients failing to achieve even this degree of relief.

Doses above those needed for treatment of depression may be more effective for some patients. A therapeutic dose for 6-10 weeks may be required to observe a clinical response. Response tends to be slow and continue for at least 12 weeks (the common duration of OCD pharmacologic clinical trials), unlike the use of these same antidepressants in the treatment of major depressive episodes, where responses are more often seen somewhat earlier.

Several treatment studies suggest a possible role for norepinephrine (NE) in cases of OCD. A subset of patients reportedly shows greater clinical improvement with a combination of 5-HT and NE reuptake inhibition as compared with treatment with SSRIs alone. These have included patients treated with clomipramine and patients whose SSRI treatment was augmented with an NE reuptake inhibitor, such as desipramine. (See Treatment-Resistance Strategies.)

Preclinical studies and several case reports and small clinical trials have provided some preliminary support for the therapeutic use of specific glutamatergic agents.[6, 7] However, these agents (eg, memantine, N -acetylcysteine, riluzole, topiramate, glycine) have varied glutamatergic and other pharmacologic effects, so if they are demonstrated to be effective, clarifying any therapeutic mechanism of action will be important.

The first double-blind, placebo-controlled trial conducted by Berlin et al suggests topiramate augmentation for treatment-resistant OCD may be beneficial for compulsions but not obsessions.[33] The modification of glutamatergic function may be partly responsible for the improved response in compulsions seen with topiramate.

Previous
Next

Behavior Therapy

Behavior therapy is a first-line treatment that should be undertaken with a psychotherapist who has specific training and experience in such treatment (most commonly a behaviorally trained psychologist). Some patients will not undertake this therapy, with perhaps 25% rejecting it and 25% dropping out of behavioral therapy, but it should definitely be encouraged if a competent behavioral therapist is available.

Exposure and response (or ritual) prevention (ERP) is the important and specific core element in behavior therapy for OCD. The patient rank orders OCD situations he or she perceives as threatening, and then the patient is systematically exposed to symptom triggers of gradually increasing intensity, while the individual is to suppress his or her usual ritualized response. This is generally challenging and often quite distressing for the patient, but when effectively done, it promotes unlearning of the strong link that has existed between having an urge and giving into the urge.

When a patient does not respond in the face of a potent trigger, extinction of the response can take place. The patient’s significant others should be involved when possible, and they may have to be willing to change their responses to the patient (eg, not provide requested reassurance to irrational doubts).

Simpson et al reported on a multimodal residential treatment program that integrated ERP treatment for OCD with ERP treatment that targeted eating pathology. Patients also received a supervised eating plan, medication management, and social support. The results were significant decreases in OCD severity, eating disorder severity, and depression in the 56 patients with both disorders. Greater improvement was seen in patients with bulimia nervosa than in those with anorexia nervosa.[34]

ERP is now usually administered as part of a broader program of CBT specifically designed for OCD. Other elements of CBT that are used include identifying and challenging the cognitive distortions of OCD symptoms (eg, intolerance of uncertainty, black-and-white thinking, focusing on unlikely extreme possibilities instead of viewing the future in a balanced manner, ascribing overimportance to thoughts, excessive concern about the importance of one's thoughts, inflated sense of responsibility). After making the patient aware of his or her irrational thoughts, the therapist works to have the patient counter them with more rational thoughts and do cost/benefit analyses regarding performing his or her rituals.

Meditation and relaxation techniques may be useful, but not during active ERP, as the effectiveness of these exercises requires that the patient experience a significant level of discomfort and then not respond with his or her characteristic rituals. A patient may benefit from a self-help book in conducting ERP (eg, Foa and Reid, 2001[31] ), and workbooks are available for CBT as well. When recommending such a book, the treating physician should be familiar with its content.

A related approach, described by Dr. Jonathan Grayson, focuses on getting the patient to accept living with uncertainty as it relates to his or her obsessional ideas, and to prepare an individualized script to reinforce this attitude.[35]

Psychodynamic psychotherapy alone has generally not been found to be helpful in ameliorating OCD symptoms. It may, however, be useful in working on a patient's resistance to accepting recommended treatments or in helping the patient to appreciate the interpersonal effects that his or her OCD symptoms are having on others.[30]

Previous
Next

Treatment-Resistance Strategies

Strategies should always include an assessment of complicating diagnoses, medication compliance, drug dose, and duration of therapy.

The presence of a comorbid diagnosis that has not been addressed, such as depression or panic disorder, can interfere with clinical recovery, and identification may guide the choice of interventions. Targeted interventions might include, for example, lithium or antipsychotic augmentation or ECT for depression.

Interventions for patients with treatment resistance include the following:

  • Change or increase in medication (eg, increase dose or prescribe different SSRI or clomipramine)
  • More intensive CBT

Other interventions, which have not received an FDA indication for OCD include the following:

  • Addition of an NE reuptake inhibitor, such as desipramine, to an SSRI, or a trial of venlafaxine
  • Addition of a typical or atypical antipsychotic, especially in patients with a history of tics
  • Augmentation with buspirone
  • Addition of inositol
  • Sole or augmented use of selected glutamatergic agents [6, 7]
  • Deep brain stimulation [11, 12] or cingulotomy neurosurgery [13] for severe and intractable cases (see Surgical Care)

Some clinicians feel that individuals with comorbid Tourette disorder or with hoarding as their principal OCD symptom may be more likely to be treatment resistant, although there is significant variation in treatment response, regardless of the particular presenting symptomatology.

Previous
Next

Surgical Care

Neurosurgical treatment of OCD is performed at a limited number of centers and is reserved for patients with severe and refractory symptoms. The most common small series use a specific small lesion (eg, cingulotomy) or deep brain stimulation. Current clinical trials are also exploring the application of transcranial magnetic stimulation (TMS), a noninvasive treatment, for OCD.

One surgical technique involves the stereotactic placement of bilateral lesions in the anterior cingulate cortex. A case series of 18 patients showed a 28% response rate, with an additional 17% showing a partial response. No significant adverse neurologic or cognitive sequelae were noted.

A deep brain stimulation technique consists of implanting a device to electrically stimulate the subthalamic nucleus. A crossover study in 17 patients with severe, refractory OCD in which patients received 3 months of active stimulation and 3 months of sham stimulation in randomized order, found that there was significantly more improvement during the active stimulation periods. However, serious adverse events were substantial and included intracerebral hemorrhage and infection.[12]

In February 2009, the FDA approved the use of Reclaim Deep Brain Stimulation Therapy for individuals with chronic, severe OCD. This device is an implanted medical device that is designed to target a region called the ventral capsule/ventral striatum, which is in the anterior limb of the internal capsule of the brain.

The Obsessive Compulsive Foundation can provide a list of centers with experience in neurosurgical OCD treatment.

Previous
Next

Consultations

While treatment approaches for OCD are now well described in the literature, many clinicians remain unfamiliar with the features and management of this disorder. Consultation should be sought if the treating physician is unfamiliar or uncomfortable with the diagnosis, or if they feel they have exhausted the interventions with which they feel comfortable.

Consultations should be sought if the clinician is not experienced in treating patients with OCD with cognitive-behavioral therapy, including exposure and ritual prevention, if the patient might possibly cooperate with this treatment. For extreme, unremitting cases, consultation may be sought for neurosurgical interventions.

Previous
Next

Long-Term Monitoring

OCD is a disorder that may involve remissions and relapses, but it usually does not entirely remit without definitive behavioral therapy. Patients in continuing treatment should be monitored for the presence or worsening of comorbid disorders, which may include substance use disorders and major depression, and any risk of suicidal ideation or behavior.

Previous
 
 
Contributor Information and Disclosures
Author

William M Greenberg, MD Medical Director, Mental Health Association of Rockland County; Professor, St George's University School of Medicine; Private Practice

William M Greenberg, MD is a member of the following medical societies: American Medical Association, American Psychiatric Association

Disclosure: Nothing to disclose.

Chief Editor

David Bienenfeld, MD Professor, Departments of Psychiatry and Geriatric Medicine, Wright State University, Boonshoft School of Medicine

David Bienenfeld, MD is a member of the following medical societies: American Medical Association, American Psychiatric Association, Association for Academic Psychiatry

Disclosure: Nothing to disclose.

Acknowledgements

Mohammed A Memon, MD Chairman and Attending Geriatric Psychiatrist, Department of Psychiatry, Spartanburg Regional Medical Center

Mohammed A Memon, MD is a member of the following medical societies: American Association for Geriatric Psychiatry, American Medical Association, and American Psychiatric Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References
  1. Karno M, Golding JM, Sorenson SB, Burnam MA. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry. 1988 Dec. 45(12):1094-9. [Medline].

  2. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989 Nov. 46(11):1006-11. [Medline].

  3. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA: American Psychiatric Association; 2013.

  4. Pepper J, Hariz M, Zrinzo L. Deep brain stimulation versus anterior capsulotomy for obsessive-compulsive disorder: a review of the literature. J Neurosurg. 2015 May. 122 (5):1028-37. [Medline].

  5. Andrade C. Ondansetron augmentation of serotonin reuptake inhibitors as a treatment strategy in obsessive-compulsive disorder. J Clin Psychiatry. 2015 Jan. 76 (1):e72-5. [Medline].

  6. Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry. 2005 Sep 1. 58(5):424-8. [Medline].

  7. Greenberg WM, Benedict MM, Doerfer J, Perrin M, Panek L, Cleveland WL, et al. Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults. J Psychiatr Res. 2009 Mar. 43(6):664-70. [Medline].

  8. Haghighi M, Jahangard L, Mohammad-Beigi H, Bajoghli H, Hafezian H, Rahimi A, et al. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). Psychopharmacology (Berl). 2013 Mar 23. [Medline].

  9. Ghaleiha A, Entezari N, Modabbernia A, Najand B, Askari N, Tabrizi M, et al. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res. 2013 Feb. 47(2):175-80. [Medline].

  10. Rodriguez CI, Kegeles LS, Levinson A, Feng T, Marcus SM, Vermes D, et al. Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept. Neuropsychopharmacology. 2013 Jun 19. [Medline].

  11. Greenberg BD, Malone DA, Friehs GM, Rezai AR, Kubu CS, Malloy PF, et al. Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology. 2006 Nov. 31(11):2384-93. [Medline].

  12. Mallet L, Polosan M, Jaafari N, Baup N, Welter ML, Fontaine D, et al. Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Engl J Med. 2008 Nov 13. 359(20):2121-34. [Medline].

  13. Jung HH, Kim CH, Chang JH, Park YG, Chung SS, Chang JW. Bilateral anterior cingulotomy for refractory obsessive-compulsive disorder: Long-term follow-up results. Stereotact Funct Neurosurg. 2006. 84(4):184-9. [Medline].

  14. Stetka B, Correll, C. A Guide to DSM-5: Hoarding, Skin-Picking, and Rethinking OCD. Available. Medscape Medical News. Available at http://www.medscape.com/viewarticle/803884_7. Accessed: July 1, 2013.

  15. APA. Obsessive-Compulsive and Related Disorders. Available at http://www.dsm5.org/Documents/Obsessive%20Compulsive%20Disorders%20Fact%20Sheet.pdf.. Accessed: July 1, 2013.

  16. Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry. 1995 Jan. 52(1):53-60. [Medline].

  17. Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ, Henk HJ. Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis. Psychopharmacology (Berl). 1998 Apr. 136(3):205-16. [Medline].

  18. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006 Jul. 11(7):622-32. [Medline].

  19. Baxter LR Jr, Schwartz JM, Bergman KS, Szuba MP, Guze BH, Mazziotta JC, et al. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry. 1992 Sep. 49(9):681-9. [Medline].

  20. Pittenger C, Krystal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx. 2006 Jan. 3(1):69-81. [Medline].

  21. Wu K, Hanna GL, Rosenberg DR, Arnold PD. The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. Pharmacol Biochem Behav. 2012 Feb. 100(4):726-35. [Medline]. [Full Text].

  22. van Grootheest DS, Cath DC, Beekman AT, Boomsma DI. Twin studies on obsessive-compulsive disorder: a review. Twin Res Hum Genet. 2005 Oct. 8(5):450-8. [Medline].

  23. Carey G, Gottesman I. Twin and family studies of anxiety, phobic, and obsessive disorders. Klein DF, Rabkin JG. Anxiety: New Research and Changing Concepts. New York: Raven Press; 2000.

  24. Arnold PD, Rosenberg DR, Mundo E, Tharmalingam S, Kennedy JL, Richter MA. Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obessive-compulsive disorder: a preliminary study. Psychopharmacology. August 2004. 174:530-538.

  25. Arnold PD, Sicard T, Burroughs E, Richter MA, Kennedy JL. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch Gen Psychiatry. 2006 Jul. 63(7):769-76. [Medline].

  26. Denys D, Van Nieuwerburgh F, Deforce D, Westenberg H. Association between the dopamine D2 receptor TaqI A2 allele and low activity COMT allele with obsessive-compulsive disorder in males. Eur Neuropsychopharmacol. 2006 Aug. 16(6):446-50. [Medline].

  27. Dickel DE, Veenstra-VanderWeele J, Cox NJ, Wu X, Fischer DJ, Van Etten-Lee M, et al. Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Arch Gen Psychiatry. 2006 Jul. 63(7):778-85. [Medline].

  28. Lin PY. Meta-analysis of the association of serotonin transporter gene polymorphism with obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Apr 13. 31(3):683-9. [Medline].

  29. Rapoport JL. The Boy Who Couldn't Stop Washing: The Experience and Treatment of Obsessive-Compulsive Disorder. paperback. New York: Penguin Putnam; 2001.

  30. [Guideline] American Psychiatric Association Work Group on Obsessive-Compulsive Disorder. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. July 2007. 164(suppl):1-56. [Full Text].

  31. Foa EB, Wilson R. Stop Obsessing!: How to Overcome Your Obsessions and Compulsions. Revis ed. New York: Bantam Dell; 2001.

  32. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders - Patient Edition (SCID-I/P, 11/2002 revision). New York: Biometrics Research Department, New York State Psychiatric Institute; November 2002.

  33. Berlin HA, Koran LM, Jenike MA, et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2011 May. 72(5):716-21. [Medline].

  34. Simpson HB, Wetterneck CT, Cahill SP, Steinglass JE, Franklin ME, Leonard RC, et al. Treatment of obsessive-compulsive disorder complicated by comorbid eating disorders. Cogn Behav Ther. 2013 Mar. 42(1):64-76. [Medline].

  35. Grayson J. Freedom From Obsessive Compulsive Disorder: A Personalized Recovery Program for Living With Uncertainty. New York: Berkley Publishing Group; 2004.

  36. Celexa (citalopram hydrobromide) [package insert]. St. Louis, Missouri: Forest Pharmaceuticals, Inc. August, 2011. Available at [Full Text].

  37. US Food and Drug Administration. Celexa (citalopram hydrobromide): Drug safety communication – abnormal heart rhythms associated with high doses. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm269481.htm. Accessed: August 24, 2011.

  38. Komossa K, Depping AM, Meyer M, Kissling W, Leucht S. Second-generation antipsychotics for obsessive compulsive disorder. Cochrane Database Syst Rev. 2010 Dec 8. 12:CD008141. [Medline].

  39. FDA Public Health Advisory: Suicidality in Children and Adolescents Being Treated With Antidepressant Medications. FDA Website. October 15, 2004. 1-3. [Full Text].

  40. FDA Proposes New Warnings About Suicidal Thinking, Behavior in Young Adults Who Take Antidepressant Medications. FDA Website. May 2, 2007. 1-3. [Full Text].

  41. A Message From APA President Dilip Jeste, M.D., on DSM-5. Available at http://www.psychnews.org/files/DSM-message.pdf. Accessed: December 1, 2012.

  42. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.

  43. Bartz JA, Hollander E. Is obsessive-compulsive disorder an anxiety disorder?. Prog Neuropsychopharmacol Biol Psychiatry. 2006 May. 30(3):338-52. [Medline].

  44. Bienvenu OJ, Samuels JF, Wuyek LA, Liang KY, Wang Y, Grados MA, et al. Is obsessive-compulsive disorder an anxiety disorder, and what, if any, are spectrum conditions? A family study perspective. Psychol Med. 2012 Jan. 42(1):1-13. [Medline].

  45. Brooks M. Adjunctive CBT First Choice for Refractory OCD. Medscape Medical News. Sep 11 2013. [Full Text].

  46. Castle DJ, Phillips KA. Obsessive-compulsive spectrum of disorders: a defensible construct?. Aust N Z J Psychiatry. 2006 Feb. 40(2):114-20. [Medline]. [Full Text].

  47. Dell'Osso B, Altamura AC, Allen A, Marazziti D, Hollander E. Epidemiologic and clinical updates on impulse control disorders: a critical review. Eur Arch Psychiatry Clin Neurosci. 2006 Dec. 256(8):464-75. [Medline]. [Full Text].

  48. Melville NA. CBT beats adjunctive antipsychotic for refractory OCD. Medscape Medical News. April 11, 2013. [Full Text].

  49. Simpson HB, Foa EB, Liebowitz MR, et al. Cognitive-Behavioral Therapy vs Risperidone for Augmenting Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. Sep 11 2013. [Medline].

 
Previous
Next
 
Table. Categorizing Obsessions and Compulsions
Obsessions Commonly Associated Compulsions
Fear of contamination Washing, cleaning
Need for symmetry, precise arranging Ordering, arranging, balancing, straightening until "just right"
Unwanted sexual or aggressive thoughts or images Checking, praying, “undoing” actions, asking for reassurance
Doubts (eg, gas jets off, doors locked) Repeated checking behaviors
Concerns about throwing away something valuable Hoarding
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.